Integrative omics and phase IIa clinical trial identify TNF as key node in autoimmune hepatitis

BACKGROUND & AIMS: Patients with autoimmune hepatitis (AIH) experience increased mortality and severe side effects from nonspecific immunosuppressive therapy, highlighting an urgent need for targeted treatment approaches. Here, we aimed to delineate the cellular and molecular network underlying AIH within its spatial context and to validate a key therapeutic target in a clinical trial. METHODS: We employed computational modelling, multi-omics analyses, and functional experiments to map the immune landscape of AIH. In addition, we conducted a steroid-free open-label phase IIa clinical trial using infliximab, a TNF-targeting antibody, in patients with AIH. RESULTS: Our studies revealed that myeloid cell and hepatocyte-derived IL-15 promotes cytotoxicity and proliferation of liver auto-aggressive CD8(+) T cells. Full execution of their cytotoxic program is licensed by TNF derived from clonally expanded liverresident CD4(+) T cells. AIH hepatocytes respond to TNF by increasing expression of adhesion molecules, making them targets for both CD8(+) and CD4(+) T cells. In the clinical trial, targeting TNF with infliximab demonstrated efficacy as an entirely steroid-free AIH treatment. CONCLUSIONS: These findings elucidate the immune network in AIH and identify TNF as one of the central network nodes. Accordingly, our findings provide the basis for novel targeted, steroid-free immune therapies, including the use of infliximab. CLINICAL TRIAL NUMBER: European Union Clinical Trials Register (EudraCT No.: 2017-003311-19).